Low- and conventional-dose TMP-SMX combination equally effective in Pneumocystis Pneumonia in non-HIV infected patients suggests a new study published in the CHEST
In this multicenter retrospective cohort study, we included patients diagnosed with non-HIV PCP and treated with TMP-SMX between June 2006 and March 2021 at three institutions. The patients were classified into low- (TMP <12.5 mg/kg/day) and conventional-dose groups (TMP 12.5–20 mg/kg/day). The primary endpoint was 30-day mortality, and the secondary endpoints were 180-day mortality, adverse events of grade 3 or greater per the Common Terminology Criteria for Adverse Events v5.0, and initial treatment completion rates. Background characteristics were adjusted using the overlap weighting method with propensity scores.
Results
Fifty-five patients in the low-dose and 81 in the conventional-dose groups were evaluated. In the overall cohort, the average age was 70.7 years, and the proportion of females was 55.1%. The average dose of TMP-SMX was 8.71 mg/kg/day in the low-dose group and 17.78 mg/kg/day in the conventional-dose group. There was no significant difference in 30-day mortality (6.7% vs. 18.4%, P=0.080) or 180-day mortality (14.6% vs. 26.1%, P=0.141) after adjusting for patient background characteristics. The incidence of adverse events, especially nausea and hyponatremia, was significantly lower in the low-dose group (29.8% vs. 59.0%, P=0.005). The initial treatment completion rates were 43.3% and 29.6% in the low-dose and conventional-dose groups (P=0.158), respectively.
Survival was similar between the low- and conventional-dose TMP-SMX groups, and low-dose TMP-SMX was associated with reduced adverse events in patients with non-HIV PCP.
Reference:
Tatsuya Nagai, Hiroki Matsui, Haruka Fujioka, Yuya Homma, Ayumu Otsuki, Hiroyuki Ito, Shinichiro Ohmura, Toshiaki Miyamoto, Daisuke Shichi, Watari Tomohisa, Yoshihito Otsuka, Kei Nakashima, Low- Versus Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Non-Human Immunodeficiency Virus-Infected Patients: A Multi-Center, Retrospective Observational Cohort Study,CHEST,2023, ISSN 0012-3692, https://doi.org/10.1016/j.chest.2023.08.009
https://www.sciencedirect.com/science/article/pii/S0012369223052698
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.